指南与共识银屑病与炎症性皮肤病

比利时关于银屑病治疗达标结局定义的共识

A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2020-01-02

该共识采用文献回顾、专家讨论、3轮eDelphi调查和患者焦点小组,为中度至重度寻常型银屑病定义治疗达标(T2T)复合结局。共识设定「理想」和「可接受」目标,包含PASI、瘙痒VAS、DLQI、功能受限VAS、安全性和耐受性等多维指标,达标时间定为所有治疗启动后12周。

要点

  • T2T复合结局涵盖PASI、瘙痒、皮损、DLQI、功能、安全性和耐受性等维度。
  • 理想目标要求更严格,可接受目标允许影响某些药物使用的条件。
  • 所有治疗的达标时间设定为启动后12周。

核心结论

  • 该新型T2T复合结局可帮助临床医生和患者就治疗目标共同决策,指导后续治疗步骤,实现疾病的紧密控制管理。

研究设计与样本

  • 研究包括文献回顾、与关键意见领袖讨论、招募有中度至重度银屑病管理经验的皮肤科医生、3轮eDelphi调查和患者焦点小组。
  • 共进行5次讨论,3轮eDelphi调查平均每轮19名参与者。
  • 共识定义为至少80%参与者同意。

主要发现

  • T2T结局设定基于医患共同决策、皮肤科医生对共病的认识和转诊、患者适当的治疗依从性。
  • 定义了「理想」和「可接受」目标,后者指限制某些药物使用的条件。
  • T2T结局为多维复合结局,包括≥ΔPASI90/75或PGA≤1、瘙痒VAS≤1、无困扰性皮损、DLQI≤1/3、日常功能受限VAS≤1、安全性≤轻度副作用以及治疗完全/轻度耐受(分别对应理想和可接受目标)。
  • 所有治疗的T2T结局达标时间设定为启动后12周。
  • 安全性在任何时候均不应超过轻度副作用。

关键数值与推荐

  • 理想目标:≥ΔPASI90/75或PGA≤1,瘙痒VAS≤1,无困扰性皮损,DLQI≤1,日常功能受限VAS≤1,安全性≤轻度副作用,治疗完全耐受。
  • 可接受目标:≥ΔPASI90/75或PGA≤1,瘙痒VAS≤1,无困扰性皮损,DLQI≤3,日常功能受限VAS≤1,安全性≤轻度副作用,治疗轻度耐受。
  • 达标时间:所有治疗启动后12周。

临床怎么用

  • 临床医生和患者可基于T2T复合结局共同决策治疗目标。
  • 以12周为达标时间点评估治疗反应,指导后续治疗调整。
  • 治疗过程中需持续监测安全性,不应超过轻度副作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Treat-to-target (T2T) is an algorithm to reach a predefined outcome. Here, we define a T2T outcome for moderate-to-severe psoriasis vulgaris. METHODS: Briefly, the study included a literature review, discussions with key opinion leaders, recruitment of additional dermatologists with experience in managing moderate-to-severe psoriasis, 3 eDelphi survey rounds and a patient focus group. Relevant topics were selected during discussions prior to the survey for the statements. Surveys were based on the eDelphi methodology for consensus-building using a series of statements. Consensus was defined as at least 80% of participants agreeing. A psoriasis patient focus group provided feedback on topic selection and outcome. RESULTS: A total of 5 discussions were held, and 3 eDelphi rounds were conducted with an average of 19 participants per round. The T2T outcome was set assuming shared decision between patient and dermatologist, awareness and referral for comorbidities by the dermatologist and appropriate treatment adherence by the patient. We defined 'ideal' and 'acceptable' targets; the latter referring to conditions restricting certain drugs. The T2T outcome was multidimensional, including ≥ ΔPASI90/75 or PGA ≤ 1, itch VAS score ≤ 1, absence of disturbing lesions, DLQI ≤ 1/3, incapacity daily functioning VAS score ≤ 1, safety ≤ mild side-effects and full/mild tolerability of treatment for the ideal and acceptable target, respectively. Finally, time to achieve the T2T outcome was set at 12 weeks after initiation for all treatments. At all times, safety should not exceed the presence of mild side-effects. CONCLUSION: With this novel T2T composite outcome for psoriasis, clinicians and patients can make shared decisions on the treatment goals they envisage, as a guidance for future treatment steps - leading to a tight control management of the disease.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Grine L, de la Brassinne M, Ghislain PD, et al. A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management. J Eur Acad Dermatol Venereol. 2020. PMID: 31749264. doi:10.1111/jdv.16104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。